126 related articles for article (PubMed ID: 19914274)
1. WITHDRAWN: Requirement of lipocalin 2 in breast cancer.
Leng X; Ding T; Lin H; Wang Y; Wu Y; Arlinghaus RB
Adv Enzyme Regul; 2009 Nov; ():. PubMed ID: 19914274
[No Abstract] [Full Text] [Related]
2. Lipocalin 2 could predict circulating MMP9 levels in patients with breast cancer.
Bahrun U; Wildana W; Rahmawati H; Kurniawan LB; Hamdani W
Breast Dis; 2021; 40(S1):S115-S117. PubMed ID: 34057126
[TBL] [Abstract][Full Text] [Related]
3. The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer.
Sung H; Choi JY; Lee SA; Lee KM; Han S; Jeon S; Song M; Lee Y; Park SK; Yoo KY; Noh DY; Ahn SH; Kang D
BMC Cancer; 2012 May; 12():193. PubMed ID: 22640376
[TBL] [Abstract][Full Text] [Related]
4. Lipocalin 2 promotes lung metastasis of murine breast cancer cells.
Shi H; Gu Y; Yang J; Xu L; Mi W; Yu W
J Exp Clin Cancer Res; 2008 Dec; 27(1):83. PubMed ID: 19077278
[TBL] [Abstract][Full Text] [Related]
5. No effect of NGAL/lipocalin-2 on aggressiveness of cancer in the MMTV-PyMT/FVB/N mouse model for breast cancer.
Cramer EP; Glenthøj A; Häger M; Juncker-Jensen A; Engelholm LH; Santoni-Rugiu E; Lund LR; Laerum OD; Cowland JB; Borregaard N
PLoS One; 2012; 7(6):e39646. PubMed ID: 22737251
[TBL] [Abstract][Full Text] [Related]
6. Lipocalin-1 Expression as a Prognosticator Marker of Survival in Breast Cancer Patients.
Zhang X; Cui Y; He M; Jiao Y; Yang Z
Breast Care (Basel); 2020 Jun; 15(3):272-280. PubMed ID: 32774222
[TBL] [Abstract][Full Text] [Related]
7. Elevated plasma level of neutrophil gelatinase-associated lipocalin (NGAL) in patients with breast cancer.
Wei CT; Tsai IT; Wu CC; Hung WC; Hsuan CF; Yu TH; Hsu CC; Houng JY; Chung FM; Lee YJ; Lu YC
Int J Med Sci; 2021; 18(12):2689-2696. PubMed ID: 34104101
[No Abstract] [Full Text] [Related]
8. Neutrophil gelatinase-associated lipocalin protein as a biomarker in the diagnosis of breast cancer: A meta-analysis.
Wang Y; Zeng T
Biomed Rep; 2013 May; 1(3):479-483. PubMed ID: 24648972
[TBL] [Abstract][Full Text] [Related]
9. Molecular docking analysis of docetaxel analogues as duel lipocalin 2 inhibitors.
Ponnulakshmi R; Rekha UV; Padmini R; Perumal S; Saravanan R; Vishnupriya V; Vijayalakshmi P; Selvaraj J
Bioinformation; 2020; 16(6):438-443. PubMed ID: 32884206
[TBL] [Abstract][Full Text] [Related]
10. Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion.
Villodre ES; Hu X; Larson R; Finetti P; Gomez K; Balema W; Stecklein SR; Santiago-Sanchez G; Krishnamurthy S; Song J; Su X; Ueno NT; Tripathy D; Van Laere S; Bertucci F; Vivas-MejĂa P; Woodward WA; Debeb BG
Mol Oncol; 2021 Oct; 15(10):2752-2765. PubMed ID: 34342930
[TBL] [Abstract][Full Text] [Related]
11. Lipocalin 2: a potential therapeutic target for breast cancer metastasis.
Hu C; Yang K; Li M; Huang W; Zhang F; Wang H
Onco Targets Ther; 2018; 11():8099-8106. PubMed ID: 30519052
[TBL] [Abstract][Full Text] [Related]
12. Lipocalin 2: a multifaceted modulator of human cancer.
Yang J; Moses MA
Cell Cycle; 2009 Aug; 8(15):2347-52. PubMed ID: 19571677
[TBL] [Abstract][Full Text] [Related]
13. Requirement of lipocalin 2 for chronic myeloid leukemia.
Arlinghaus R; Leng X
Leuk Lymphoma; 2008 Apr; 49(4):600-3. PubMed ID: 18398717
[TBL] [Abstract][Full Text] [Related]
14. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer.
Kubben FJ; Sier CF; Hawinkels LJ; Tschesche H; van Duijn W; Zuidwijk K; van der Reijden JJ; Hanemaaijer R; Griffioen G; Lamers CB; Verspaget HW
Eur J Cancer; 2007 Aug; 43(12):1869-76. PubMed ID: 17604154
[TBL] [Abstract][Full Text] [Related]
15. Lipocalin 2 promotes breast cancer progression.
Yang J; Bielenberg DR; Rodig SJ; Doiron R; Clifton MC; Kung AL; Strong RK; Zurakowski D; Moses MA
Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3913-8. PubMed ID: 19237579
[TBL] [Abstract][Full Text] [Related]
16. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients.
Fernández CA; Yan L; Louis G; Yang J; Kutok JL; Moses MA
Clin Cancer Res; 2005 Aug; 11(15):5390-5. PubMed ID: 16061852
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous expression of the lipocalin NGAL in primary breast cancers.
Stoesz SP; Friedl A; Haag JD; Lindstrom MJ; Clark GM; Gould MN
Int J Cancer; 1998 Dec; 79(6):565-72. PubMed ID: 9842963
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.
Kurozumi S; Alsaeed S; Orah N; Miligy IM; Joseph C; Aljohani A; Toss MS; Fujii T; Shirabe K; Green AR; Aleskandarany MA; Rakha EA
Breast Cancer Res Treat; 2020 Feb; 179(3):557-564. PubMed ID: 31707510
[TBL] [Abstract][Full Text] [Related]
19. Relationships of lipocalin 2 with breast tumorigenesis and metastasis.
Leng X; Wu Y; Arlinghaus RB
J Cell Physiol; 2011 Feb; 226(2):309-14. PubMed ID: 20857428
[TBL] [Abstract][Full Text] [Related]
20. NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene.
Fougère M; Gaudineau B; Barbier J; Guaddachi F; Feugeas JP; Auboeuf D; Jauliac S
Oncogene; 2010 Apr; 29(15):2292-301. PubMed ID: 20101218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
